NFKB1 and B-cell non-Hodgkin lymphoma: For example, Griner et al. [34] suggested that ibrutinib’s inhibition of nuclear factor kappa B (NFκB) might counteract its protective function against anthracycline-induced DNA damage to explain the ibrutinib-doxorubicin synergism in B-cell lymphoma cells.